The EGF 61A/G polymorphism - A predictive marker for recurrence of liver metastases from colorectal cancer

Wiener Klinische Wochenschrift

Volumn 121, Issue 19-20, 2009, Pages 638-643

  Kovar, Florian M ^a   Thallinger, Christiane ^a   Marsik, Claudia L ^a   Perkmann, Thomas ^a   Puhalla, Harald ^a   Haslacher, Helmuth ^a   Wrba, Fritz ^a   Wagner, Oswald F ^a   Gruenberger, Thomas ^a   Endler, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CRCLM (colorectal cancer liver metastases); EGF 61A G polymorphism; Human

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; GENOMIC DNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; GROUPS BY AGE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; RETROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

AUSTRIA; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 71149120153     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-009-1250-3     Document Type: Article

References (30)

1. EK Abdalla JN Vauthey LM Ellis V Ellis R Pollock KR Broglio, et al. 2004 Recurrence and outcome following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg 239 818 825 10.1097/01.sla.0000128305.90650.71 15166961 discussion 825-827 (Pubitemid 38669432)
2. AC Ashley C Deschamps SR Alberts 2006 Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases Clin Colorectal Cancer 6 32 37 10.3816/CCC.2006.n.018 16796789
3. Austrian Breast and Colorectal Cancer Study Group ÖGfCO, Österreichische Gesellschaft für Chirurgie Österreichische Gesellschaft für Hämatologie und Onkologie Österreichische Gesellschaft für Pathologie Österreichische Gesellschaft für Radioonkologie Medizinische Strahlenphysik und Strahlenbiologie and Österreichische Röntgengesellschaft 2004 Empfehlungen zur Diagnostik und multimodaler Primärtherapie des Rektumkarzinoms Wien Klin Wochenschr 117 154 171 10.1007/s00508-005-0323-1
4. J Baselga 2002 Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 2 8 10.1634/theoncologist.7-suppl-4-2 1:CAS:528:DC%2BD38XnsFOiurw%3D 12202782
5. AJ Danielsen NJ Maihle 2002 The EGF/ErB receptor family and apoptosis Growth Factors 20 1 15 10.1080/08977190290022185 1:CAS:528:DC%2BD38XjvV2gt7k%3D 11999214 (Pubitemid 34693055)
6. E Raymond S Faivre JP Armand 2000 Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl 15 23 10.2165/00003495-200060001-00002 1:CAS:528:DC%2BD3cXptVegtrw%3D 11129168 discussion 41-42
7. M Shahbazi V Pravica N Nasreen H Fakhoury AA Fryer RC Strange 2002 Association between functional polymorphism in EGF gene and malignant melanoma Lancet 359 9304 397 401 10.1016/S0140-6736(02)07600-6 1:CAS:528: DC%2BD38XhtFyrs7g%3D 11844511 (Pubitemid 34158948)
8. E Vauleon N Auger A Benouaich F Laigle-Donadey G Kaloshi J Lejeune, et al. 2007 The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma Cancer Genet Cytogenet 172 33 37 10.1016/j.cancergencyto.2006.07.013 1:CAS:528:DC%2BD28Xhtlarsr3F 17175377 (Pubitemid 44920265)
9. DA Bhowmick Z Zhuang SD Wait RJ Weil 2004 A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease Cancer Research 64 1220 1223 10.1158/0008-5472.CAN-03-3137 1:CAS:528:DC%2BD2cXhtleisLs%3D 14973082 (Pubitemid 38235584)
10. RT Poon S Fan 2003 Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after resection in Chinese patients Surg Oncol Clin N Am 12 35 60 10.1016/S1055-3207(02)00086-8 12735128 (Pubitemid 36204978)
11. The Brisbane 2000 Terminology of Liver Anatomy and Resections (2000) HPB 2: 333-339
12. HPB (Oxford) 2002, 4: 99-100
13. I Okamoto F Roka J Krögler G Endler S Kaufmann S Tockner, et al. 2006 The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma J Invest Dermatol 126 2242 2246 10.1038/sj.jid.5700377 1:CAS:528:DC%2BD28Xps1aisb4%3D 16691190 (Pubitemid 44413171)
14. H Ueno H Mochizuki K Hatsuse K Hase T Yamamoto 2000 Ann Surg 231 59 66 10.1097/00000658-200001000-00009 1:STN:280:DC%2BD3c7gtVSmug%3D%3D 10636103 (Pubitemid 30043940)
15. S Balzan J Belgihiti O Farges S Ogata A Sauvanet D Delefosse, et al. 2005 The "50:50 criteria" on postoperative day 5, an accurate predictor of liver failure and death after hepatectomy Ann Surg 242 824 828 10.1097/01.sla.0000189131.90876.9e 16327492 (Pubitemid 41714060)
16. S Iwatsuki I Dvorchik JR Madariaga JW Marsh F Dodson A Bonham, et al. 1999 Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system J Am Coll Surg 189 291 299 10.1016/S1072-7515(99) 00089-7 1:STN:280:DyaK1MzpvF2juw%3D%3D 10472930 (Pubitemid 29408866)
17. B Nordlinger M Guiguet J Vailant 1996 Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients Cancer 77 1254 1262 10.1002/(SICI)1097- 0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I 1:STN:280: DyaK287pslCiuw%3D%3D 8608500 (Pubitemid 26102322)
18. B Cady MD Stone 1991 The role of surgical resection of liver metastases in colorectal carcinoma Semin Oncol 18 399 406 1:STN:280:DyaK3MzitVWnsg%3D%3D 1650502
19. B Gentner A Wein RS Croner I Zeittraeger RM Wirtz F Roedel, et al. 2009 Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases Anticancer Res 29 67 74 1:CAS:528:DC%2BD1MXjtFGgs7s%3D 19331134
20. L Pleyer P Went G Russ E Primz V Faber H-J Roewert, et al. 2007 Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein c Wien Klin Wochenschr 119 254 258 10.1007/s00508-007-0774-7 1:CAS:528:DC%2BD1cXos1Wr 17492354 (Pubitemid 46895795)
21. S Zakari J Donohue FG Que MB Farnell CD Schleck DM Ilstrup, et al. 2007 Hepatic resection for colorectal metastases Ann Surg 246 183 191 10.1097/SLA.0b013e3180603039 (Pubitemid 47196514)
22. Ichikawa A, Kotake K, Matsui T, Koyama Y, Suda K, Yao T (2009) Classification of colorectal carcinoma obtained from the combination of DNA ploidy and genetic alterations serves as a significant prognostic factor. J Gastroenterol e-Pub ahead of print [April 8th, 2009]
23. K Riemann H Struwe H Alakus B Obermaier KJ Schmitz KW Schmid, et al. 2009 Association of GNBA intro-1 haplotypes with survival in patients with UICC stage III and IV colorectal carcinoma Anticancer Res 29 1271 1274 1:CAS:528:DC%2BD1MXltFCgsrc%3D 19414374
24. P McColgan P Sharma 2009 Polymorphisms of matrix metalloproteinase 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects Int J Cancer Int J Cancer 125 1473 1478 10.1002/ijc.24441 1:CAS:528:DC%2BD1MXovVemurY%3D
25. CM Rocha-Lima H Soares LE Raez R Singal 2007 EGFR targeting of solid tumors Cancer Control 14 295 304 17615536
26. H Takiuchi 2007 Cetuximab Gan To Kagaku Ryoho 34 1192 1195 1:CAS:528:DC%2BD2sXhtVKlt7nM 17687200
27. J Tabernero 2007 The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents Mol Cancer Res 5 203 220 10.1158/1541-7786.MCR-06-0404 1:CAS:528:DC%2BD2sXjt1Srsbo%3D 17374728 (Pubitemid 46569773)
28. J Stoehlmacher 2007 Prediction of efficacy and side effects of chemotherapy in colorectal cancer Recent Results Cancer Res 176 81 88 10.1007/978-3-540-46091-6-8 1:CAS:528:DC%2BD2sXpsleisLo%3D 17607918
29. Russo A, Corsale S, Cammareri P, Agnese V, Cascio S, di Fede G, et al (2005) Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy. J Cell Physiol: 742-749
30. S Yoon S Kim M Gonen N Heffernan K Detwiller W Jarnagin, et al. 2006 Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases Ann Surg Oncol 13 353 362 10.1245/ASO.2006.03.060 16474912